Revolution in hepatitis C antiviral therapy

British Medical Bulletin

Volumn 113, Issue 1, 2015, Pages 31-44

  Sadler, Matthew D ^a   Lee, Samuel S ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

asunaprevir; boceprevir; daclatasvir; direct acting antivirals; Hepatitis C virus; ledipasvir; peg interferon; ribavirin; simeprevir; sofosbuvir; telaprevir

Indexed keywords

ANTIVIRUS AGENT; ASUNAPREVIR; DACLATASVIR; DASABUVIR; GRAZOPREVIR; LEDIPASVIR PLUS SOFOSBUVIR; MK 8742; OMBITASVIR; PARITAPREVIR; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; UNCLASSIFIED DRUG;

ANTIVIRAL THERAPY; ARTICLE; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; HUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRAL CLEARANCE; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; DRUG EFFECTS; GENETICS; GENOTYPE; HEPACIVIRUS; LIVER CIRRHOSIS; PRACTICE GUIDELINE; TRENDS;

ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; PRACTICE GUIDELINES AS TOPIC;

EID: 84924559884     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldv004     Document Type: Article

References (69)

1. EASL Clinical Practice Guidelines. Management of hepatitis C virus infection. J Hepatol 2014;60:392-420.
2. Lavanchy D. The global burden of hepatitis C. Liver Int 2009;29(Suppl. 1):74-81.
3. Coffin CS, Lee SS. Recent advances in pegylated inter-feron antiviral therapy of chronic hepatitis C. AntiInfective Agents Med Chem 2006;5:1-9.
4. Afdhal NH. The natural history of hepatitis C. Semin Liver Dis 2004;24(Suppl. 2):3-8.
5. Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008;48:148-62.
6. John-Baptiste A, Krahn M, Heathcote J, et al. The natural history of hepatitis C infection acquired through injection drug use: meta-analysis and meta-regression. J Hepatol 2010;53:245-51.
7. Swain MG, Lai M-Y, Shiffman ML, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and riba-virin. Gastroenterology 2010;139:1593-601.
8. Lee SS, Bain VG, Peltekian K, et al. Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice. Aliment Pharmacol Ther 2006;23:397-408.
9. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401.
10. Chung RT, Andersen J, Volberding P, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus riba-virin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004;351:451-9.
11. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351:438-50.
12. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004;292:2839-48.
13. Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (Baltimore, Md) 2011;54:1433-44.
14. Manns MP, McHutchison JG, Gordon SC, et al. Peginter-feron alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
15. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
16. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206.
17. Jacobson IM, McHutchison JG, Dusheiko G, et al. Tela-previr for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16.
18. Lee SS, Roberts SK, Berak H, et al. Safety of peginter-feron alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients. Liver Int 2012;32: 1270-7.
19. Chopra A, Klein PL, Drinnan T, et al. How to optimize HCV therapy in genotype 1 patients: management of side-effects. Liver Int 2013;33(Suppl. 1):30-4.
20. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-17.
21. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreat-ment of HCV infection. N Engl J Med 2011;364: 2417-28.
22. Hézode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890. J Hepatol 2013;59:434-41.
23. Lam AM, Murakami E, Espiritu C, et al. PSI-7851, a pronucleotide of beta-D-2′-deoxy-2′-fluoro-2′-C-methy-luridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. Antimicrob Agents Chemother 2010;54:3187-96.
24. Lalezari JP, Nelson DR, Hyland RH, et al. Once daily sofosbuvir plus ribavirin for 12 and 24 weeks in treatment-naïve patients with HCV infection: the Quantum Study. J Hepatol 2013;58(Suppl. 1):S346.
25. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013;368:34-44.
26. Osinusi A, Meissner EG, Lee Y-J, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 2013;310:804-11.
27. Sulkowski MS, Rodriguez-Torres M, Lalezari JP, et al. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in patients co-infected with HIV (PHOTON-1). Hepatology (Baltimore, Md) 2013;58:313A-4A.
28. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-87.
29. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368:1867-77.
30. Zeuzem S, Dusheiko G, Salupere R, et al. Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial. Hepatology (Baltimore, Md) 2013;58:733A-4A.
31. Ruane PJ, Ain D, Riad J, et al. Sofosbuvir plus ribavirin in the treatment of chronic HCV genotype 4 infection in patients of Egyptian ancestry. Hepatology (Baltimore, Md) 2013;58:736A.
32. Federal Drug Administration. Background Package for NDA 205123 Simeprevir (TMC435) [Internet]. fda.gov. 2013 [cited 2014 Mar 17]. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AntiviralDrugsAdvisoryCommittee/UCM371623.pdf (17 March 2014, date last accessed).
33. Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014;384:403-13.
34. Manns M, Marcellin P, Poordad F, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014;384:414-26.
35. Forns X, Lawitz E, Zeuzem S, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014;146:1669-79.
36. Zeuzem S, Berg T, Gane E, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology 2014;146:430-6.
37. Moreno C, Hezode C, Marcellin P, et al. Once-daily simeprevir (TMC435) with peginterferon/ribavirin in treatment-naive or treatment-experienced chronic HCV genotype 4-infected patients: final results of a phase iii trial. J Hepatol 2014;60(1 Suppl):S535.
38. Pol S, Ghalib RH, Rustgi VK, et al. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis 2012;12:671-7.
39. Suzuki F, Toyota J, Ikeda K, et al. A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection. Antivir Ther (Lond) 2014;19:491-9.
40. Izumi N, Yokosuka O, Kawada N, et al. Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1. Antivir Ther (Lond) 2014;19:501-10.
41. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofos-buvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889-98.
42. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without Cirrhosis. N Engl J Med 2014;370:1879-88.
43. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483-93.
44. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:1594-603.
45. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:1604-14.
46. Ferenci P, Nyberg A, Enayati P, et al. Pearl-III: 12 weeks of ABT-450/r/267+ABT-333 achieved SVR in 99% of 419 treatment-naive HCV genotype 1b-infected adults with or without ribavirin. J Hepatol 2014;60(1 Suppl): S527.
47. Poordad F, Hézode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014;370:1973-82.
48. Hezode C, Marcellin P, Pol S, et al. Results from the phase 2 Pearl-I study: interferon-free regimens of ABT-450/r + ABT-267 with or without ribavirin in patients with HCV genotype 4 infection. J Hepatol 2014;60(1 Suppl):S24.
49. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised Study. Lancet 2014;384:1756-65.
50. Lawitz E, Ghalib R, Rodriguez-Torres M, et al. Simepre-vir plus sofosbuvir with/without ribavirin in HCV genotype 1 prior null-responder/treatment-naive patients (COSMOS Study): primary endopoint (SVR12) results in patients with metavir F3-F4 (cohort 2). J Hepatol 2014;60(Suppl):S524.
51. AASLD/IDSA/IAS-USA. Recommendations for Testing, Managing, and Treating Hepatitis C. http://www. hcvguidelines.org (24 April 2014, date last accessed).
52. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2014. J Hepatol 2014;61:373-95.
53. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370:211-21.
54. Chayama K, Takahashi S, Toyota J, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asuna-previr, in hepatitis C virus genotype 1b-infected null responders. Hepatology (Baltimore, Md) 2012;55:742-8.
55. Lok AS, Gardiner DF, Hézode C, et al. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol 2014;60:490-9.
56. Suzuki Y, Ikeda K, Suzuki F, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 2013;58:655-62.
57. Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology (Baltimore, Md) 2014;59:2083-91.
58. Manns M, Pol S, Jacobson I, et al. All oral dual therapy with daclatasvir and asunaprevir in patients with HCV genotype 1B infection: phase 3 study results. J Hepatol 2014;60(Suppl):S524-5.
59. Kao JH, Heo J, Yoffe B, et al. Efficacy and safety of daclatasvir in combination with asunaprevir (DCV +ASV) in cirrhotic and non-cirrhotic patients with HCV genotype 1b: results of the Hallmark Dual Study. J Hepatol 2014;60(1 Suppl):S527-8.
60. Hezode C, Serfaty L, Vierling JM, et al. Safety and efficacy of the all-oral regimen of MK-5172/MK-8742±riba-virin in treatment-naive, non-cirrhotic, patients with hepatitis C virus genotype 1 infection: the C-Worthy Study. J Hepatol 2014(1 Suppl);60:S5.
61. Lawitz E, Hezode C, Gane E, et al. Efficacy and safety of MK-5172 and MK-8742±ribavirin in hepatitis C genotype 1 infected patients with cirrhosis or previous null-response: the C-Worthy Study. J Hepatol 2014;60(1 Suppl):S25-6.
62. Congly SE, Lee SS. Editorial: can we afford the new direct-acting antivirals for treatment of genotype 1 hepatitis C? Aliment Pharmacol Ther 2014;40:983-4.
63. Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/riba-virin. J Hepatol 2005;43:425-33.
64. Dogan UB, Akin MS, Yalaki S. Sustained virological response based on the week 4 response in hepatitis C virus genotype 1 patients treated with peginterferons α-2a and α-2b, plus ribavirin. Eur J Gastroenterol Hepatol 2013;25:1317-20.
65. Ferenci P, Laferl H, Scherzer T-M, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008;135:451-8.
66. Leroy V, Serfaty L, Bourlière M, et al. Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver. Liver Int 2012;32:1477-92.
67. Lee SS, Sherman M, Ramji A, et al. Randomised clinical trial: the efficacy of treatment, guided by a shorter duration of response, using peginterferon alfa-2a plus riba-virin for hepatitis C virus other than genotypes 2 or 3. Aliment Pharmacol Ther 2012;35:37-47.
68. Yu M-L, Dai C-Y, Huang J-F, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology (Baltimore, Md) 2008;47:1884-93.
69. Liu C-H, Liu C-J, Lin C-L, et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008;47:1260-9.